Orexigen Insists Revised Contrave Data Should Not Affect Timing Of NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA tells the biotech corrections to secondary endpoint data for one pivotal study for its diet pill filing comprise only a clinical amendment.
You may also be interested in...
Contrave Advisory Committee Date May Give Orexigen Late-Mover Advantage
Earlier panel critiques of Contrave rivals should provide insight on how FDA is weighing risk versus benefit in obesity space.
Contrave Advisory Committee Date May Give Orexigen Late-Mover Advantage
Earlier panel critiques of Contrave rivals should provide insight on how FDA is weighing risk versus benefit in obesity space.
Medivation, Orexigen Highlight Late-Stage Strategies for Closely-Watched Drugs
Medivation will push on with Phase III trials despite an Alzheimer's failure, while Orexigen says a competitor's obesity drug could affect partnering plans.